Konstantinos Zarogoulidis

TL;DR: The primary endpoint was disease-free survival in the overall population, the no-chemotherapy population, and patients with a potentially predictive gene signature, which could not identify a gene signature predictive of clinical benefit to MAGE-A3 immunotherapeutic.

TL;DR: In advanced stage IIIB/IV or inoperable NSCLC pts, a multidisciplinary treatment should be offered consisted of 4 cycles of cisplatin-based chemotherapy plus a 3(rd) generation cytotoxic agent or a cytostatic drug.

TL;DR: Of particular interest for the scientific community is the discovery of clinically exploitable biomarkers associated with specific phenotypes of the disease that may lead to targeted therapy based on phenotype and this is perhaps the future of therapeutics in COPD.

TL;DR: An extensive review of drug delivery systems, pharmaceuticals, patient monitoring, methods of enhancing inhaled drug deposition, safety and efficacy, and also additional applications of inhaled chemotherapy and its advantages and disadvantages are presented, finding regional chemotherapy to the lung parenchyma for lung cancer is feasible and efficient.

TL;DR: It is crucial to define asthma, COPD and overlap syndrome (ACOS), as notable clinical entities, which they share common pathologic and functional features, but they are characterized from differences in lung function, acute exacerbations, quality of life, hospital impact and mortality.